Related Experiment Video
Updated: Jan 15, 2026

Assessment of the Metabolic Profile of Primary Leukemia Cells
Published on: November 21, 2018
Molecular profile of atypical Leydig cell tumours
Muhammad F K Choudhry1, Diogo Caires1, Yaser Gamallat1
1Department of Pathology & Laboratory Medicine, University of Calgary Cumming School of Medicine & Alberta Precision Labs, Calgary, Alberta, Canada.
Aims:
To investigate histological and copy number variations (CNVs) in Leydig cell tumours (LCTs) of the testis. Although usually benign, a small minority of cases can be associated with a poor prognosis and metastasis.
Methods:
We performed whole copy number analysis to compare the genomic profile of atypical (defined by the presence of any atypical features) versus benign LCTs. Our sample consisted of one malignant (with biopsy-proven metastasis), five atypical and five benign cases.
Results:
We found increased genomic instability in the malignant tumour and within two out of five (40%) atypical cases. One benign case revealed a likely pathogenic mutation in the neurofibromatosis type 2 gene, but all benign cases lacked genomic instability. Apart from the malignant case (which had metastatic spread to the scrotal skin), all remaining atypical cases did not reveal evidence of recurrence or metastatic spread.
Conclusion:
CNVs by themselves are not sufficient to discriminate between cases that are benign versus those with malignant potential, without the use of histomorphological parameters. Genomic instability was only detected in the malignant and atypical cases, and not in any of the benign tumours. Thus, genomic instability may represent an early step in malignant progression. The presence of metastasis remains the only malignant criterion for LCTs.
More Related Videos
10:29Semi-automatic PD-L1 Characterization and Enumeration of Circulating Tumor Cells from Non-small Cell Lung Cancer Patients by Immunofluorescence
Published on: August 14, 2019
10:27Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts
Published on: July 25, 2020